generic competition

Latest Headlines

Latest Headlines

Pfizer plans direct-to-consumer Lipitor sales

Lately, almost every day we've heard of a new Pfizer ($PFE) strategy for hanging on to Lipitor sales after the drug faces generic competition. Discounts, co-pay cards, rebates, conversion to OTC--the

FTC chief laments 63% boost in generic settlements

You can't accuse Federal Trade Commission Chairman Jon Leibowitz of being a quitter. The agency chief is on his generic settlements soapbox again, saying that the number of deals delaying copycat

Lilly revenue grows, but costs drive profits down

Eli Lilly is facing a few lean years ahead, but it managed to grow sales during the first quarter. The company's revenue increased by 6 percent on higher sales of several of its key drugs. And thanks

GSK partner holds off generic rival for Lovaza

GlaxoSmithKline and its Lovaza partner may escape generic competition on the drug until 2015. Pronova BioPharma, which makes the fish-oil-derived treatment, inked a deal with Apotex that allows the

Herper: Cheap Lipitor could increase health costs

In a report this morning, Forbes' Matthew Herper writes that a war over Lipitor could contribute to higher healthcare premiums--even for those who don't use the drug. As Herper notes, Pfizer late

Legal challenges on branded drug patents way up

Drug companies have been besieged by a rising tide of challenges to patents on brand-name drugs in recent years. Indeed, lawsuits challenging patents on branded drugs have risen from 81 in 2005 to

Supremes asked to take on pay-for-delay

The controversy over the so-called pay-to-delay settlements is bubbling up to the U.S. Supreme Court, Pharmalot reports. Three pharmacy chains and a wholesaler have asked the court to review the

Analysts: Lipitor may live longer than we think

Could it be that Pfizer's Lipitor won't suffer an immediate K.O. punch from generic competition? Rather than the sudden-and-sharp loss of billions in Lipitor revenues, Pfizer might actually see a

APP Pharma thwarted in Angiomax patent suit

Medicines Co. is another step closer to clearing its patent protection on its key money-earner Angiomax. The company has been fighting the U.S. Patent and Trademark Office to get it to reconsider its

Judge unimpressed by Sanofi's Lovenox argument

Sanofi-Aventis (NYSE: SNY) isn't giving up on protecting Lovenox from generic competition--not even after a federal judge refused its request for a preliminary injunction against the copycats. "The